Sheela Foam, Aster DM Healthcare get Sebi''s nod for IPO
Sheela Foam, Aster DM Healthcare get Sebis nod for IPO Two companies -- Sheela Foam and Aster DM Healthcare -- have received markets regulator Sebi''s approval to float initial public offerings (IPO). Sheela Foam, maker of Sleepwell mattresses, had filed draft papers with Sebi in July, while Aster DM Healthcare, which runs hospitals in India and Middle East, had applied for IPO in June.
The markets regulator issued its final ''observations'' on the the draft documents of Sheela Foam and Aster DM Healthcare on November 2 and November 3, respectively, as per the latest update available with Securities and Exchange Board of India (Sebi).
Sebi''s ''observations'' is necessary for any company to launch the public offer.
Sheela Foam filed draft red herring prospectus (DRHP) with Sebi for its Rs 510-crore offer for sale.
The company, which has 12 manufacturing facilities, developed a pan-India distribution network consisting of over 100 exclusive distributors, more than 2,000 exclusive retail dealers and over 2,500 multi-brand outlets. The firm exports its products to 25 countries.
Sheela Foam also manufactures foam-based home comfort products like mattresses, furniture-cushioning, pillows, cushions and sofa-cum-beds.
Edelweiss Financial Services and ICICI Securities are the merchant bankers of the initial public offer (IPO).
Aster DM Healthcare''s IPO comprises up to 57,685,166 equity shares. This include fresh issuance of shares as well as offer for sale by existing investors.
The issue is being managed by Kotak Mahindra Capital, Bank of America Merrill Lynch, Goldman Sachs, Edelweiss, ICICI Securities, JM Financial and SBI Capital Market.
So far this year, 24 companies have launched their initial public offerings.
Salute to the people applying for this ipo....there is sale on world class pharma stocks and people are still applying for such a small company at such high valuations with such high risk.
148. gamble| Link| Bookmark|
November 10, 2016 7:44:21 AM
(1600+ Posts, 3900+ Likes)
Ipo looks very confusing.....take call look risky ...and fully based on future prospective.....mkt condition has settled for now....don''t know whether this microbio can command 27x PE(future) with single manufacturing unit..!!
....if HNIs don''t show any interest better to avoid....!!
I think this ipo will be the badest performer of the year...
1.The company Book value is 11.5 approx
2.The company EPS is 1.5 ruppees approx for last financial year which is the higgest in these year..
3.The company has shown last year profit only as company want to raise money via ipo these year...
4.The company price band is 76-80.The company has issued bonus shares in the ratio 3:2 to reduce the price band as the investor will watch price band to be in the range 76-80...but if the company does not issued bonus shares then the price band 190-200...
5.As per the current book value and Eps the present price band should be ruppees 20-30....
6.Finally,according to me this issue is not to be subscribed and it will not be able to arrange the money from the market too....As per the 1st day subscription only .03% of the ipo is subscribed.............No Anchor investors,No QIB subscription....It will be totally depend on Retail subscribtion......
Thank you......Reply if you like the comment.........I will be thankful to you....
The listing is depend on number of times IPO is subscribed...........But ipo is not good......